SCHEMBL31744643

SCHEMBL31744643

Cc1ccccc1Oc1c[nH]c2ccc(Br)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.51
GPR84 Q9NQS5 1/20 0.44
NR4A2 P43354 1/20 0.43
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRA3 P34903 1/20 0.41
GABRB2 P47870 1/20 0.41
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41
TUBA4A P68366 1/20 0.41
TUBB4B P68371 1/20 0.41
TUBB3 Q13509 1/20 0.41
TUBB2A Q13885 1/20 0.41
TUBB8 Q3ZCM7 1/20 0.41
TUBA3E Q6PEY2 1/20 0.41
TUBA1A Q71U36 1/20 0.41
TUBA1C Q9BQE3 1/20 0.41
TUBB6 Q9BUF5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31744680 0.85 IDO1 (0.50) IDO1GPR84NR4A2GABRA1GABRB1
SCHEMBL31744712 0.84 IDO1 (0.49) IDO1GPR84NR4A2TUBB4ATUBB
SCHEMBL31744608 0.84 IDO1 (0.50) IDO1GPR84TUBB4ATUBBTUBA3C
SCHEMBL31744877 0.82 IDO1 (0.48) IDO1GPR84NR4A2TUBB4ATUBB
SCHEMBL31744580 0.82 IDO1 (0.48) IDO1GPR84NR4A2TUBB4ATUBB
SCHEMBL31744902 0.81 IDO1 (0.47) IDO1GPR84NR4A2TUBB4ATUBB
SCHEMBL31744596 0.80 IDO1 (0.48) IDO1GPR84NR4A2TUBB4ATUBB
SCHEMBL31744588 0.79 GPR84 (0.48) IDO1GPR84NR4A2GABRA1GABRB1
SCHEMBL31744707 0.79 IDO1 (0.45) IDO1GPR84NR4A2TUBB4ATUBB
SCHEMBL31744595 0.76 GPR84 (0.50) IDO1GPR84NR4A2GABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US claimed
US-20250382269-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US disclosed
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382269-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CD14, MIF, NOD2 IDO1 38/4885GPR84 4183/4885NR4A2 1398/4885
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CD14, MIF, NOD2 IDO1 38/4885GPR84 4183/4885NR4A2 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.